Aduro’s CRS-207 for Mesothelioma Wins Orphan Drug Status From EMA
The European Medicines Agency has granted Aduro Biotech’s mesothelioma candidate orphan drug designation.
Given orphan status by the FDA in March, CRS-207 immunotherapy is being tested alongside standard chemotherapy in a Phase 1b study for patients with malignant pleural mesothelioma. The drugmaker says it will launch a similar Phase 3 trial in the first half of next year, skipping mid-stage research to propel the candidate forward.
[Article continues at original source]
Asbestos-Mesothelioma Case Evaluation Form
Free. Confidential. No Obligation.